摘要
咪唑立宾是一种免疫抑制剂，它作用于细胞合成过程中，选择性抑制淋巴细胞增殖，发挥免疫抑制作用。它在。肾移植后的抗排斥反应，减缓狼疮性肾炎病理加重，减少IgA肾病的蛋白尿及肾小球硬化风险，减少激素依赖型。肾病综合征蛋白尿及复发频次，降低过敏性紫癜性肾炎蛋白尿水平等方面均取得一定的疗效，且安全性较高，不良反应较少，但由于循证依据不多，仍需多中心大样本的观察。
Mizoribine, an immunosuppressive agent, plays a role in cell synthesis process, selectively inhibits lymphocyte proliferation, and suppresses immune function. It has obtained certain curative effect in resist- ance the rejection after kidney transplantation, slowing down lupus nephritis pathological progress, reducing the proteinuria and the risk of glomerular sclerosis on IgA nephropathy, decreasing the recurrence frequency and pro- teinuria on steroid-dependent nephrotic syndrome and reducing proteinuria level on Henoch-Schoenlein purpura nephritis. It＇s safer, fewer side effects ,but for lacking evidences ,large sample still be needed.
出处
《国际儿科学杂志》
2012年第3期252-254,共3页
International Journal of Pediatrics
基金
江苏省重点医学人才基金资助（RC2007115）
关键词
咪唑立宾
肾移植
狼疮性肾炎
IGA肾病
肾病综合征
Mizoribine
Kidney transplantation
Lupus nephritis
IgA nephropathy
Nephrotic syndrome
